独立微孔陶瓷与自体骨在器械辅助后外侧脊柱融合中的非劣效性随机对照试验
这项多中心、患者与观察者盲法、随机、患者内对照的非劣效性试验纳入100例接受胸腰椎器械辅助后外侧融合的成人,比较双相磷酸钙(AttraX® Putty)与自体骨的融合效果。基于87例患者146个节段的分析显示,AttraX Putty侧融合率为55%,自体骨侧为52%,差异2.3%(90%CI -9.1%至+13.7%),排除15%非劣效界值,支持其作为独立骨移植替代物。
要点
- AttraX Putty侧1年融合率55%,自体骨侧52%,总体融合率71%。
- 融合率差异2.3%(90%CI -9.1%至+13.7%),排除15%非劣效界值。
- 结果支持AttraX Putty作为胸腰椎后外侧融合的独立骨移植替代物。
核心结论
- AttraX Putty作为独立骨移植替代物在器械辅助胸腰椎后外侧融合中不劣于自体骨。
研究设计与样本
- 多中心、患者与观察者盲法、随机、患者内对照的非劣效性试验,纳入100例接受初次单或多节段胸腰椎器械辅助后外侧融合的非创伤成人。
- 每个患者一侧随机分配AttraX Putty,对侧应用自体骨作为自身对照。
主要发现
- 49例男性、51例女性,平均年龄55.4±12.0岁(范围27-79岁)。
- 三分之二患者接受单节段融合,62%附加椎间融合。
- 主要分析基于87例患者146个器械节段,AttraX Putty侧融合率55%,自体骨侧52%,总体融合率71%。
- 融合率差异2.3%(90%CI -9.1%至+13.7%),排除15%非劣效界值。
关键数值与推荐
- 主要疗效终点为1年随访CT评估的融合情况,每节段每侧评分为融合、可疑融合或不融合。
- 多节段融合校正后每侧单一评分,非劣效界值为15%,使用90%置信区间检验。
临床怎么用
- 对于胸腰椎器械辅助后外侧融合,AttraX Putty可作为自体骨的独立替代物使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: in the rest of the article written as patient- and observer-blinded, multicenter, randomized, intrapatient controlled, noninferiority trial. OBJECTIVE: The aim of this study was to determine noninferiority of a biphasic calcium-phosphate (AttraX® Putty) as a bone graft substitute for autograft in instrumented posterolateral fusion (PLF). SUMMARY OF BACKGROUND DATA: Spinal fusion with autologous bone graft is a frequently performed surgical treatment. Several drawbacks of autografting have driven the development of numerous alternatives including synthetic ceramics. However, clinical evidence for the standalone use of these materials is limited. METHODS: This study included 100 nontraumatic adults who underwent a primary, single- or multilevel, thoracolumbar, instrumented PLF. After instrumentation and preparation for grafting, the randomized allocation side of AttraX® Putty was disclosed. Autograft was applied to the contralateral side of the fusion trajectory, so each patient served as his/her own control. For the primary efficacy outcome, PLF was assessed at 1-year follow-up on computed tomography scans. Each segment and side was scored as fused, doubtful fusion, or nonunion. After correction for multilevel fusions, resulting in a single score per side, the fusion performance of AttraX Putty was tested with a noninferiority margin of 15% using a 90% confidence interval (CI). RESULTS: There were 49 males and 51 females with a mean age of 55.4 ± 12.0 (range 27-79) years. Two-third of the patients underwent a single-level fusion and 62% an additional interbody fusion procedure. The primary analysis was based on 87 patients, including 146 instrumented segments. The fusion rate of AttraX Putty was 55% versus 52% at the autograft side, with an overall fusion rate of 71%. The 90% CI around the difference in fusion performance excluded the noninferiority margin (difference = 2.3%, 90% CI = -9.1% to +13.7%). CONCLUSION: The results of this noninferiority trial support the use of AttraX Putty as a standalone bone graft substitute for autograft in instrumented thoracolumbar PLF. LEVEL OF EVIDENCE: 1.
引用
- Lehr AM, Oner FC, Delawi D, et al. Efficacy of a Standalone Microporous Ceramic Versus Autograft in Instrumented Posterolateral Spinal Fusion: A Multicenter, Randomized, Intrapatient Controlled, Noninferiority Trial. Spine (Phila Pa 1976). 2020. PMID: 32080013. doi:10.1097/BRS.0000000000003440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。